Literature DB >> 18816632

Absence of ESR1 amplification in a series of breast cancers.

José Adélaïde, Pascal Finetti, Emmanuelle Charafe-Jauffret, Julien Wicinski, Jocelyne Jacquemier, Christos Sotiriou, François Bertucci, Daniel Birnbaum, Max Chaffanet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18816632     DOI： 10.1002/ijc.23786

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  10 in total

Review 1.  Mechanisms of aromatase inhibitor resistance.

Authors:  Cynthia X Ma; Tomás Reinert; Izabela Chmielewska; Matthew J Ellis
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

2.  Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan.

Authors:  Jim-Ray Chen; Tsan-Yu Hsieh; Huang-Yang Chen; Kun-Yan Yeh; Kuo-Su Chen; Yi-Che ChangChien; Mariann Pintye; Liang-Che Chang; Cheng-Cheng Hwang; Hui-Ping Chien; Yuan-Chun Hsu
Journal:  Virchows Arch       Date:  2014-04-23       Impact factor: 4.064

3.  Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.

Authors:  B Ejlertsen; J Aldridge; K V Nielsen; M M Regan; K L Henriksen; A E Lykkesfeldt; S Müller; R D Gelber; K N Price; B B Rasmussen; G Viale; H Mouridsen
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

Review 4.  Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate.

Authors:  Frederik Holst
Journal:  World J Clin Oncol       Date:  2016-04-10

5.  Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

Authors:  Rinath Jeselsohn; Roman Yelensky; Gilles Buchwalter; Garrett Frampton; Funda Meric-Bernstam; Ana Maria Gonzalez-Angulo; Jaime Ferrer-Lozano; Jose A Perez-Fidalgo; Massimo Cristofanilli; Henry Gómez; Carlos L Arteaga; Jennifer Giltnane; Justin M Balko; Maureen T Cronin; Mirna Jarosz; James Sun; Matthew Hawryluk; Doron Lipson; Geoff Otto; Jeffrey S Ross; Addie Dvir; Lior Soussan-Gutman; Ido Wolf; Tamar Rubinek; Lauren Gilmore; Stuart Schnitt; Steven E Come; Lajos Pusztai; Philip Stephens; Myles Brown; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2014-01-07       Impact factor: 12.531

Review 6.  ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.

Authors:  Rinath Jeselsohn; Gilles Buchwalter; Carmine De Angelis; Myles Brown; Rachel Schiff
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

7.  ESR1 gene amplification: another mechanism regulating the cellular levels of ERα.

Authors:  Ke-Da Yu; Zhi-Ming Shao
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

8.  Genome profiling of ERBB2-amplified breast cancers.

Authors:  Fabrice Sircoulomb; Ismahane Bekhouche; Pascal Finetti; José Adélaïde; Azza Ben Hamida; Julien Bonansea; Stéphane Raynaud; Charlène Innocenti; Emmanuelle Charafe-Jauffret; Carole Tarpin; Farhat Ben Ayed; Patrice Viens; Jocelyne Jacquemier; François Bertucci; Daniel Birnbaum; Max Chaffanet
Journal:  BMC Cancer       Date:  2010-10-08       Impact factor: 4.430

Review 9.  Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?

Authors:  Sanaz Tabarestani; Marzieh Motallebi; Mohammad Esmaeil Akbari
Journal:  Iran J Cancer Prev       Date:  2016-08-13

10.  Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer.

Authors:  Wenzhen Zhu; Chongyang Ren; Yulei Wang; Lingzhu Wen; Guochun Zhang; Ning Liao
Journal:  Onco Targets Ther       Date:  2020-01-21       Impact factor: 4.147
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.